Suppr超能文献

糖巨肽预处理可降低变应原致敏,减轻即刻皮肤超敏反应,并预防过敏反应。

Pretreatment with glycomacropeptide reduces allergen sensitization, alleviates immediate cutaneous hypersensitivity and protects from anaphylaxis.

机构信息

Department of Microbiology, Basic Science Center, Autonomous University of Aguascalientes, Aguascalientes, Mexico.

出版信息

Clin Exp Immunol. 2012 Oct;170(1):18-27. doi: 10.1111/j.1365-2249.2012.04631.x.

Abstract

Allergic disorders are characterized by the involvement of allergen-specific immunoglobulin (Ig)E antibodies and T helper type 2 (Th2) cells. The search for new therapies for allergic diseases has been the primary focus of interest for many investigators in recent years. Glycomacropeptide (GMP) is a biologically active component of milk that exhibits a range of immunomodulatory functions. We examined whether oral administration of GMP could affect the development of allergic sensitization and the severity of immediate cutaneous hypersensitivity reactions and of anaphylaxis. Rats treated with or without GMP were ovalbumin (OVA)-sensitized and several indicators of allergy were evaluated. Pretreatment with GMP resulted in reduction of antigen-specific IgE titre in rats when sensitized with OVA. GMP administration also markedly suppressed the proliferative response of splenocytes to antigen and the production of interleukin (IL)-13 by splenocytes of sensitized animals. In addition, GMP pretreatment attenuated the intensity of the immediate cutaneous reaction induced by antigen and protected the sensitized rats from severe anaphylaxis. These data demonstrate, for the first time, that the administration of GMP prevents allergen sensitization and reduces the severity of the early-phase reaction induced by antigen in cutaneous hypersensitivity and in anaphylaxis. GMP may be used as a novel prophylactic agent for the control of allergic diseases.

摘要

变应性疾病的特征是涉及过敏原特异性免疫球蛋白 (Ig)E 抗体和辅助性 T 细胞 2 (Th2)。近年来,许多研究人员一直将寻找治疗变应性疾病的新疗法作为主要研究重点。糖巨肽 (GMP) 是牛奶中的一种生物活性成分,具有多种免疫调节功能。我们研究了口服 GMP 是否会影响过敏致敏的发展以及即刻皮肤过敏反应和过敏反应的严重程度。用或不用 GMP 处理的大鼠接受卵清蛋白 (OVA) 致敏,并评估了几种过敏指标。当用 OVA 致敏时,GMP 预处理导致大鼠抗原特异性 IgE 滴度降低。GMP 给药还显著抑制了致敏动物脾细胞对抗原的增殖反应和脾细胞产生白细胞介素 (IL)-13。此外,GMP 预处理可减轻抗原诱导的即刻皮肤反应的强度,并使致敏大鼠免受严重过敏反应的影响。这些数据首次表明,给予 GMP 可预防过敏原致敏,并降低皮肤过敏和过敏反应中抗原诱导的早期反应的严重程度。GMP 可用作控制过敏疾病的新型预防剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验